<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063384</url>
  </required_header>
  <id_info>
    <org_study_id>K01AA027573</org_study_id>
    <nct_id>NCT04063384</nct_id>
  </id_info>
  <brief_title>Acute Alcohol Response In Bipolar Disorder: a fMRI Study</brief_title>
  <acronym>BACS</acronym>
  <official_title>Subjective Response to Alcohol and Associated Neural Systems in Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol use disorders (AUDs) affect up to 60% of individuals with bipolar disorder during&#xD;
      their lifetime-a rate 3 to 5 times higher than what occurs in the general population. The&#xD;
      mechanisms that contribute to elevated rates of comorbidity are not known. Early&#xD;
      identification in individuals with bipolar disorder who are at risk for AUDs could inform&#xD;
      novel intervention strategies and improve life-long outcomes. The primary objective of this&#xD;
      protocol is to use alcohol administration procedures and functional MRI techniques to&#xD;
      investigate subjective response to alcohol, compared to placebo, and relationship with&#xD;
      functional responses of, and connectivity among, brain regions in ventral prefrontal&#xD;
      emotional networks in young adults with bipolar disorder and healthy comparison young adults.&#xD;
      Baseline clinical and structural MRI assessments will be completed in 30 bipolar and 30&#xD;
      healthy young adults (21-26 years of age, 50% women). Then, following standard beverage&#xD;
      administration procedures, participants will complete within-person, counter-balanced, fMRI&#xD;
      scans and complete measures of subjective response to alcohol while under the influence of&#xD;
      alcohol or placebo. Specifically, individual differences in the experience of stimulating,&#xD;
      sedative, and anxiolytic effects of alcohol (measured with self-report surveys) and&#xD;
      individual differences in neural responses to alcohol within ventral prefrontal emotional&#xD;
      networks will be investigated and differences in bipolar disorder compared to healthy&#xD;
      participants assessed. Functional MRI scans during a continuous performance task with&#xD;
      emotional and neutral distractors (CPT-END) and at rest will be collected while under the&#xD;
      influence of alcohol and placebo and compared. Experience of stimulating, sedative, and&#xD;
      anxiolytic effects of alcohol from self-report survey data and neural responses to emotional&#xD;
      stimuli while under the influence of alcohol compared to placebo will be the primary data&#xD;
      outcomes assessed. Additionally, associations between subjective and neural response to&#xD;
      alcohol and drinking patterns will be explored (secondary outcomes). The primary endpoint of&#xD;
      the study will be after completion of both alcohol and placebo beverage conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 60 bipolar and healthy comparison subjects (n=30 per group, 21-26 years of age,&#xD;
      50% women, with no history of a moderate/severe AUD) will be recruited from the greater&#xD;
      Austin area. Once recruited and enrolled, subjects will undergo detailed structured clinical&#xD;
      evaluations to verify inclusion and exclusion criteria, comprehensive assessment of alcohol&#xD;
      and other drug use history, and cognitive testing, followed by structural MRI assessments.&#xD;
      Following standard beverage administration procedures, they will then complete measures of&#xD;
      subjective response to alcohol and fMRI scans while under the influence of alcohol or a&#xD;
      placebo condition (counter-balanced). For each participant the first beverage session&#xD;
      assignment (whether the participant is given alcohol or the placebo beverage first) will be&#xD;
      randomized. Alcohol and placebo sessions will occur within 3 days of each other. FMRI&#xD;
      assessments will include a continuous performance task with emotional and neutral distractors&#xD;
      (CPT-END) and a resting state scan.&#xD;
&#xD;
      For both the alcohol and the placebo beverage conditions, the protocol will be the same. The&#xD;
      beverage administration sessions will occur in a private room at the University of Texas at&#xD;
      Austin in the Imaging Research Center. The table in the testing room will be wiped down with&#xD;
      alcohol prior to the participant's arrival (olfactory cue). Study staff will use an algorithm&#xD;
      to calculate individual alcohol doses based on the participants' age, sex, height, and&#xD;
      weight. Participants fast from food for 4 hours prior to their session. Before beginning&#xD;
      consumption of their beverages, they will eat a weight-adjusted, 1 calorie per pound snack of&#xD;
      pretzels. While participants eat their pretzels, study staff will mix beverages in front of&#xD;
      participants. Vodka and placebo (decarbonated tonic water) will be stored in absolute vodka&#xD;
      bottles, measured out, and combined with mixer in front of participants. Mixed drinks will be&#xD;
      poured into glasses that have been sitting face down with rims soaking in vodka. Prior to&#xD;
      giving the beverage to the participant, all drinks will get an alcohol floater (squirt of&#xD;
      absolute vodka on top of the drink). Participants will be given 20 minutes to orally consume&#xD;
      two beverages (10 minutes per beverage).&#xD;
&#xD;
      Following oral consumption and a 10 minute absorption period, breathalyzer tests will be&#xD;
      conducted to identify a .06g% ascending limb breath alcohol concentration (BrAC). Self-report&#xD;
      of subjective response to alcohol will be collected and participants will immediately enter&#xD;
      the scanner and complete the fMRI scan (acquisition parameters are identical during alcohol&#xD;
      and placebo conditions). BrAC will be tracked after the MRI scan and subjective response to&#xD;
      alcohol collected again at peak BrAC and at descending BrAC of .06g%. Consistent with NIAAA&#xD;
      guidelines for human alcohol studies, BrAC readings will continue every 30 minutes until&#xD;
      participants are below 0.04% at which time they will be escorted home. During the placebo&#xD;
      condition, participants will be given false BrAC readings. False BrAC readings given to&#xD;
      participants during the placebo session will be based on the average BrACs we record during&#xD;
      the alcohol sessions. The average time participants stay in the laboratory will be the same&#xD;
      for the placebo and alcohol beverage conditions. Participants are debriefed after completing&#xD;
      all sessions and the need for deception to ensure the placebo-controlled alcohol session will&#xD;
      be explained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neural responses to emotional stimuli (fMRI: neural responses during alcohol session minus neural responses during placebo session)</measure>
    <time_frame>baseline and up to 1 week</time_frame>
    <description>Neural responses to emotional stimuli during the alcohol and placebo sessions will be modeled. Change in neural responses (alcohol minus placebo session) in regions of interest will be calculated. Study participation to collect data (baseline clinical assessment, alcohol and placebo MRI sessions) should not take more than 1 week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in behavior (self-report surveys: alcohol session minus placebo session)</measure>
    <time_frame>baseline and up to 1 week</time_frame>
    <description>Participants will fill out self-report surveys on how they feel when they arrive to their beverage administration sessions (alcohol and placebo). They will then feel out the same self-report surveys on how intoxicated they feel during their beverage sessions (alcohol and placebo). Changes in how intoxicated they feel will be calculated for both the alcohol and placebo condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drinking patterns</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Participants will complete self-report surveys describing their drinking pattern and a structured assessment (time line follow back) to assess recent quantity, duration, and frequency of drinking. Correlations between this secondary measure and primary measures listed above will be explored.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Alcohol Drinking</condition>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be dosed to a 0.08g% blood alcohol concentration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a low dose of alcohol (placebo condition).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>alcohol beverage</intervention_name>
    <description>Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.</description>
    <arm_group_label>Alcohol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo beverage</intervention_name>
    <description>placebo beverage conditions.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for all participants:&#xD;
&#xD;
          -  between 21 and 26 years of age&#xD;
&#xD;
          -  having consumed at least 4 (men) or 3 (women) drinks on a single occasion over the&#xD;
             last year&#xD;
&#xD;
          -  euthymic at the time of study&#xD;
&#xD;
        Inclusion criteria for bipolar disorder participants:&#xD;
&#xD;
        - Meeting Diagnostic and Statistical Manual-5 Research Version (DSM-V-RV) diagnostic&#xD;
        criteria for bipolar disorder, confirmed by structured interview&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all subjects exclusion criteria include:&#xD;
&#xD;
          -  history of significant medical illness, particularly if possible changes in cerebral&#xD;
             tissue&#xD;
&#xD;
          -  neurologic abnormality including significant head trauma (loss of consciousness of&#xD;
             â‰¥5-min)&#xD;
&#xD;
          -  full Scale intelligence quotient (IQ) &lt;85&#xD;
&#xD;
          -  contraindication to MRI scanning&#xD;
&#xD;
          -  positive pregnancy test&#xD;
&#xD;
          -  history of cannabis use disorder&gt;moderate&#xD;
&#xD;
          -  history of severe AUDs&#xD;
&#xD;
          -  scores &gt; 15 on the alcohol Use Disorders Identification Test (AUDIT; part of phone&#xD;
             screen)&#xD;
&#xD;
          -  ever being in an abstinence-oriented treatment program for alcohol use&#xD;
&#xD;
          -  reporting wanting to quit drinking but not being able to&#xD;
&#xD;
          -  any medical, religious, or other reasons for not drinking alcohol&#xD;
&#xD;
          -  history of heart attack, heart trouble, high blood pressure, diabetes, or liver&#xD;
             disease&#xD;
&#xD;
          -  an adverse reaction to alcoholic beverages&#xD;
&#xD;
          -  reporting never consuming 4 (men) or 3 (women) or more drinks on a single occasion&#xD;
             over the last year&#xD;
&#xD;
          -  unwillingness to have a friend or family member drive them home after the alcohol&#xD;
             administration sessions&#xD;
&#xD;
          -  a past substance use disorder (other than alcohol, cannabis, or nicotine)&#xD;
&#xD;
        Additional exclusion criteria for bipolar disorder participants:&#xD;
&#xD;
        - not taking medications for greater than or equal to 4 weeks (i.e. participants must be&#xD;
        stable on medications)&#xD;
&#xD;
        Additional exclusion criteria for healthy comparison subjects also include:&#xD;
&#xD;
          -  any prior psychiatric hospitalizations&#xD;
&#xD;
          -  lifetime history of a neurodevelopmental disorder, affective disorder, psychotic&#xD;
             disorder, eating disorder&#xD;
&#xD;
          -  greater than 1 month of lifetime psychotropic medication. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Lippard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Austin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Coordinator</last_name>
    <phone>(512) 495-5198</phone>
    <email>behavioral.neuroimaging@austin.utexas.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>512-495-5198</phone>
      <email>behavioral.neuroimaging@austin.utexas.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Elizabeth Thomas Cox Lippard</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After study completion and publication of finding, functional neuroimaging data and behavior data collected following alcohol and placebo conditions will be shared.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>We will complete all our analyses and publish results and methodologies in scientific journals before the data are available to the research community. Data will be made available following 6 months after publication.</ipd_time_frame>
    <ipd_access_criteria>We will be collecting identifying information. Even though the final dataset will be stripped of identifiers prior to release for sharing, we believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

